FDA
-
-
-
-
-
-
-
Zentalis Pharmaceuticals Announces First Patient Dosed in ASPENOVA Phase 3 Trial of Azenosertib in Patients with Cyclin E1-Positive Platinum-Resistant Ovarian Cancer
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on Zentalis Pharmaceuticals (ZNTL)
-
-
-
-
-
-
-
Zentalis Pharmaceuticals Announces Four Azenosertib Posters Presentations at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
-
-
-
-
-
-
-
Zentalis Pharmaceuticals (ZNTL) PT Lowered to $10 at H.C. Wainwright
-
-
-
-
-
-
-
Zentalis Pharmaceuticals Announces FDA Has Lifted Partial Clinical Hold on Azenosertib Studies
-
-
-
-
-
-
-
Zentalis Pharmaceuticals (ZNTL) Resumes Trading, Down 29%
-
-
-
-
-
-
-
Zentalis Pharmaceuticals Appoints Kimberly Freeman as Chief Strategy Officer
-
323,580 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

